Bromfenac

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H12BrNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 864P0921DW, chemically known as benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)- but generally known as bromfenac, which bears US NIH Compound Identifier 60725. Bromfenac most often comes in base and sodium forms. European Medicines Agency schedules Bromfenac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05913MIG. The term BROMFENAC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). World Health Organization schedules bromfenac in its Anatomical Therapeutic Chemical (ATC) Classification. BROMFENAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bromfenac under HS 29225000 and SITC 51467. As of Q4 2014, BROMFENAC remains the US FDA Preferred Term for this commodity. Bromfenac bears US NLM identifiers UMLS ID C0054094 and NCI Concept Code C65271. SMILES: BRC1CCC(C(=O)C2C(N)C(CC(=O)O)CCC2)CC1.[NA].